Literature DB >> 8529530

Effects of zolpidem on the architecture and cyclical structure of sleep in poor sleepers.

A Besset1, M Tafti, E Villemin, P Borderies, M Billiard.   

Abstract

Effects of zolpidem, a short acting non benzodiazepine hypnotic, have been studied in eight female poor sleepers, aged 25 to 54 years, documented during two consecutive adaptation nights. Subjects were recorded according to a 22 day single blind study. Placebo was given orally at bedtime on nights 2-4, zolpidem on nights 5-20 and finally placebo on nights 21-22. Polygraphic recordings (conventional analysis) were performed on nights 1-6; 12, 13; 19-22. Parameters of sleep continuity, sleep architecture and cyclical structure of sleep were studied. Zolpidem 10 mg showed a hypnotic effect on poor sleepers. It reduced sleep latency, increased total sleep time and decreased the number of awakenings during all recorded nights. During the first post-drug night a rebound insomnia was observed in two subjects only. Zolpidem did not increase specifically stage 2 to the detriment of stages 3 and 4 but it restored them during the first nights of administration. Study of the rapid eye movements-non rapid eye movements (REM-NREM) sleep cycles structure showed that the increase of stages 3 and 4 occurred only during the first part of the night. Finally, zolpidem had no effect on REM sleep temporal distribution.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529530

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  4 in total

1.  Zolpidem induced hyponatremia: a case report.

Authors:  Shanmuga Priya S; Britto Dl; Saravanan T
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 2.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

3.  Zolpidem modified-release in insomnia.

Authors:  Cynthia Kirkwood; Jason Neill; Ericka Breden
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

4.  Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors.

Authors:  Gabrielle E Callander; Morenike Olorunda; Dominique Monna; Edi Schuepbach; Daniel Langenegger; Claudia Betschart; Samuel Hintermann; Dirk Behnke; Simona Cotesta; Markus Fendt; Grit Laue; Silvio Ofner; Emmanuelle Briard; Christine E Gee; Laura H Jacobson; Daniel Hoyer
Journal:  Front Neurosci       Date:  2013-12-03       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.